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INTRODUCTION 
Human C-peptide or ‘connecting’ peptide is a 31 amino acid chain which originates in the pancreatic
beta cells as a by-product of enzymatic cleavage of the precursor of insulin1,2. This precursor is
proinsulin and was first described by Steiner and Oyer3. Transformation of proinsulin to insulin begins
in the golgi apparatus and continues in the secretory granules of the beta cells4. Insulin and C-peptide
are secreted in equi-molar concentrations into the portal circulation5,6 but this relationship is not
preserved in the peripheral circulation due to differences in first pass metabolism by the liver and due
to insulin binding antibodies. The liver extracts approximately 50% of insulin delivered to it, in the first
pass metabolism7. This first pass metabolism of insulin is variable and unpredictable in individual
patients. Hepatic extraction of C-peptide is negligible8. Circulating insulin antibodies, found in some
patients on insulin therapy, would interfere with insulin assays, rendering them unreliable as a predictor
of residual beta cell activity. Also, the metabolic clearance rate of C-peptide is constant under different
physiological circumstances and over the range of plasma concentrations usually encountered9. Hence
C- peptide assays, which are now available, would serve as a more useful indicator of beta cell activity
and insulin secretion than peripheral insulin assays.
URINARY C-PEPTIDE 
Urinary excretion of various hormones and their metabolites have been used to calculate their secretion
rates. The potential of using this approach to measure insulin secretion is a possibility. Based on
glomerular permeability studies it can be predicted that a molecule as small as C-peptide would be
freely filtered across the glomerular basement membrane despite its negative charge10,11. Kaneko et al
first reported that appreciable quantities of C-peptide were excreted in urine in man and that urinary C-
peptide levels increased after an oral glucose load in parallel with the increase in plasma C-peptide
levels. Urinary C-peptide and creatinine excretion rates reduce in parallel so that the ratio of their 24
hour excretion rates remained constant in renal disease12. Horwitz et al13 reported that the 24 hour
urinary excretion of C-peptide in normal subjects was 36±4 ug while in type I diabetic subject was only
1.1±0.5 ug Range of urinary C-peptide in type II diabetic subjects overlapped the amounts excreted in
normal and juvenile-onset diabetic subjects. Except in uremia, C-peptide levels in 24 hours urine
collection provide an accurate reflection of average plasma levels of C-peptide and hence average
insulin secretion14.
METHODOLOGY 
Various radioimmunoassay (MA) methods are available for the detection of C-peptide. In our
laboratory a competitive radioimmunoassay in which labelled 125I C-peptide competes with C-peptide
in the patient’s sample for antibody sites is employed. First the patient sample is incubated with C-
peptide antiserum and labelled 1251 C-peptide for 14-16 hours. The antigen-antibody complexes
formed are precipitated by the help of a second antibody. The precipitate is counted for radioactivity
and patient sample concentrations are read from a calibration curve prepared from a synthetic human
C-peptide analog. Radioimmunoassays are sensitive upto 75 pg/ml. Insulin itself does not cross react
with the assay but circulating anti-insulin antibodies may react with proinsulin, the latter in turn may
react with C-peptide antibodies and thus may result in misleadingly high C-peptide assay results. C-
peptide is mainly cleared by the kidneys and associated renal disease may affect Cpeptide values.
Interference during assay is produced by lipaemia and icteric samples, however hemolyzed serum
samples produced no significant changes.
USES OF C-PEPTIDE ESTIMATION 
Measures of C-peptide levels have been most useful in the evaluation of hypoglycaemic states
especially in diagnosis of endogenous hyperinsulinemia, e.g., insulinoma. In addition to measurement
of levels, the suppression of C-peptide with insulin induced hypoglycaemia can also be checked in
insulinoma where there is a loss of C-peptide suppression. Following resection of insulinoma, C-
peptide levels can be a marker of recurrence of tumour or metastasis15. Factitious hypoglycaemia due
to exogenous insulin administration in diabetic and non-diabetic patients can also be distinguished from
excess endogenous insulin secretion by this assay. Following pancreatectomy for carcinoma of
pancreas C- peptide levels will indicate presence of residual pancreatic tissue. In patients with non-
insulin dependent diabetes (type II), insulin secretory responses after oral and intravenous glucose
challenges are decreased and decline progressively with severity of diabetes16. Peak C-peptide levels
during oral glucose tolerance test have also been shown to be a predictor of insulin requirement in
diabetic patients. In their study Turkingtoh et al17 showed that patients with C-peptide levels less than
4.0 ug/ml could not be treated without supplementation with exogenous insulin. Patients with C-
peptide reactivity levels between 4. 1-5.4 ug/ml could usually avoid ketosis without insulin therapy but
could not normalize blood glucose by weight loss alone. Patients with C-peptide levels greater than 6.0
ug/ml could normalize hyperglycaemia by weight loss alone. Other studies have also shown the value
of C-peptide to predict the insulin requirements at diagnosis of diabetes mellitus18. Also C- peptide
levels are useful to assay in type I diabetics, to see residual beta cell function which in these patients is
expected to be low in contrast to high levels in beta cell over activity in insulinomas19. Fasting C-
peptide levels have used to determine clinical type of diabetes20. Diabetic complications like
proliferative retinopathy appears to be higher in patients with low C-peptide levels21. C-peptide assays
are being used in various research orientated studies in type I and type II diabetic patients at present.
CONCLUSION 
Plasma and urinary C-peptide levels can serve as a valuable index of insulin secretion. The assay is
now available and has many diagnostic uses. It marks a significant advancement as a diagnostic tool in
the evaluation of diabetic patients as well as determining the causes of hypoglycaemia.
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